Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Bibliographic Details
Main Authors: Zarir F. Udwadia, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Wen Wu, Cynthia F. Caracta, Monika Tandon
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:International Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221001144
id doaj-07b88cf4d2af415abfa8f695973e93ea
record_format Article
spelling doaj-07b88cf4d2af415abfa8f695973e93ea2021-04-26T05:54:17ZengElsevierInternational Journal of Infectious Diseases1201-97122021-04-01105686687Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et alZarir F. Udwadia0Hanmant Barkate1Saiprasad Patil2Shabbir Rangwala3Wen Wu4Cynthia F. Caracta5Monika Tandon6Breach Candy Hospital, Mumbai, IndiaGlenmark Pharmaceuticals Limited, Mumbai, IndiaGlenmark Pharmaceuticals Limited, Mumbai, IndiaGlenmark Pharmaceuticals Limited, Mumbai, IndiaGlenmark Pharmaceuticals Ltd, Watford, UKGlenmark Pharmaceuticals, Inc., Mahwah, NJ, USACorresponding author.; Glenmark Pharmaceuticals Limited, Mumbai, Indiahttp://www.sciencedirect.com/science/article/pii/S1201971221001144
collection DOAJ
language English
format Article
sources DOAJ
author Zarir F. Udwadia
Hanmant Barkate
Saiprasad Patil
Shabbir Rangwala
Wen Wu
Cynthia F. Caracta
Monika Tandon
spellingShingle Zarir F. Udwadia
Hanmant Barkate
Saiprasad Patil
Shabbir Rangwala
Wen Wu
Cynthia F. Caracta
Monika Tandon
Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
International Journal of Infectious Diseases
author_facet Zarir F. Udwadia
Hanmant Barkate
Saiprasad Patil
Shabbir Rangwala
Wen Wu
Cynthia F. Caracta
Monika Tandon
author_sort Zarir F. Udwadia
title Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_short Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_full Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_fullStr Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_full_unstemmed Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
title_sort response to the comments received on article “efficacy and safety of favipiravir, an oral rna-dependent rna polymerase inhibitor, in mild-to-moderate covid-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial” by udwadia et al
publisher Elsevier
series International Journal of Infectious Diseases
issn 1201-9712
publishDate 2021-04-01
url http://www.sciencedirect.com/science/article/pii/S1201971221001144
work_keys_str_mv AT zarirfudwadia responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT hanmantbarkate responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT saiprasadpatil responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT shabbirrangwala responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT wenwu responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT cynthiafcaracta responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
AT monikatandon responsetothecommentsreceivedonarticleefficacyandsafetyoffavipiraviranoralrnadependentrnapolymeraseinhibitorinmildtomoderatecovid19arandomizedcomparativeopenlabelmulticenterphase3clinicaltrialbyudwadiaetal
_version_ 1721508007021379584

Similar Items